Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050298 | 1.00 | OR51E2 (0.35) | OR51E2FNTAFNTBGRIK1GRIK2 | |
| SCHEMBL3910421 | 0.87 | FNTA (0.39) | OR51E2FNTAFNTBGRIK1GRIK2 | |
| SCHEMBL3910423 | 0.87 | FNTA (0.39) | OR51E2FNTAFNTBGRIK1GRIK2 | |
| SCHEMBL20553183 | 0.81 | OR51E2 (0.31) | OR51E2GRIK1GRIK2ALDH1A1 | |
| SCHEMBL25661477 | 0.79 | GRIK1 (0.46) | GRIK1GRIK2ALOX15 | |
| Bicarbonate SCHEMBL575069 | 0.77 | CA1 (0.42) | OR51E2ALDH1A1CYP2D6ALOX15 | |
| SCHEMBL11652706 | 0.77 | TP53 (0.40) | OR51E2 | |
| SCHEMBL10457604 | 0.74 | GRIK1 (0.55) | FNTAFNTBGRIK1GRIK2ALDH1A1 | |
| SCHEMBL4891724 | 0.74 | GRIK1 (0.55) | FNTAFNTBGRIK1GRIK2ALDH1A1 | |
| SCHEMBL4891721 | 0.74 | GRIK1 (0.55) | FNTAFNTBGRIK1GRIK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | SAMHD1, POLRMT, RNGTT | OR51E2 3701/4885FNTA 1259/4885FNTB 504/4885 |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SAMHD1, POLRMT, RNGTT | OR51E2 3701/4885FNTA 1259/4885FNTB 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.